Efficacy and safety of Jinyukang capsules in the treatment of mild and moderate depression

ZHANG Hong-yan,LIU Qi,LIU Ping-lan,LI Zhan-jiang,XIE Shi-ping,GAO Cheng-ge,XU Xiu-feng,ZHANG Yan,SHU Liang

DOI: https://doi.org/10.3321/j.issn:1003-3734.2006.11.018

2006-01-01

Abstract:Objective: To assess the efficacy and safety of Jinyukang capsules versus fluoxetine in patients with mild and moderate major depression. Methods: A multicenter, randomized double blind, double dummy, positive-control clinical study recruited 293 subjects with mild and moderate depression. Subjects were randomized to receive 600 mg·d-1 Jinyukang capsules made from Hypericum extract (n = 145) or 20 mg fluoxetine (n = 148) for six weeks. The primary endpoint was to measure improvements of Hamilton rating scale for depression (HAMD17). The secondary endpoints included Hamilton rating scale for anxiety (HAMA) and clinical global impression scale (CGI). Results: At the end of therapy, subjects treated with Hypericum extract and fluoxetine all experienced significant decreases of HAMD 17 from the baseline, scoring 55. 77% and 59. 95% , respectively (P > 0. 05). The major adverse event for Hypericum-treated subjects was weight gain; the P value for such weight gain showed statistical difference (P = 0. 026). Conclusion: The Jinyukang capsules provided a therapeutic option for subjects with mild and moderate depression.